A Novel Founder Mutation in MYBPC3: Phenotypic Comparison With the Most Prevalent MYBPC3 Mutation in Spain
Rev Esp Cardiol (Engl Ed). 2017 Feb;70(2):105-114.
doi: 10.1016/j.rec.2016.06.020.
Epub 2016 Oct 28.
[Article in
English,
Spanish]
Authors
María Sabater-Molina
1
, Daniel Saura
2
, Esperanza García-Molina Sáez
3
, Josefa González-Carrillo
2
, Luis Polo
4
, Inmaculada Pérez-Sánchez
3
, María Del Carmen Olmo
2
, María José Oliva-Sandoval
2
, Roberto Barriales-Villa
5
, Pablo Carbonell
6
, Domigo Pascual-Figal
2
, Juan R Gimeno
2
Affiliations
- 1 Unidad de Cardiopatías Hereditarias, Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain. Electronic address: [email protected].
- 2 Departamento de Cardiología, Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain.
- 3 Unidad de Cardiopatías Hereditarias, Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain.
- 4 Departamento de Patología, Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain.
- 5 Unidad de Cardiopatías Hereditarias, Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.
- 6 Centro de Bioquímica y Genética Clínica, Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain.
Abstract
Introduction and objectives:
Mutations in MYBPC3 are the cause of hypertrophic cardiomyopathy (HCM). Although most lead to a truncating protein, the severity of the phenotype differs. We describe the clinical phenotype of a novel MYBPC3 mutation, p.Pro108Alafs*9, present in 13 families from southern Spain and compare it with the most prevalent MYBPC3 mutation in this region (c.2308+1 G>A).
Methods:
We studied 107 relatives of 13 index cases diagnosed as HCM carriers of the p.Pro108Alafs*9 mutation. Pedigree analysis, clinical evaluation, and genotyping were performed.
Results:
A total of 54 carriers of p.Pro108Alafs*9 were identified, of whom 39 had HCM. There were 5 cases of sudden death in the 13 families. Disease penetrance was greater as age increased and HCM patients were more frequently male and developed disease earlier than female patients. The phenotype was similar in p.Pro108Alafs*9 and in c.2308+1 G>A, but differences were found in several risk factors and in survival. There was a trend toward a higher left ventricular mass in p.Pro108Alafs*9 vs c.2308+1G>A. Cardiac magnetic resonance revealed a similar extent and pattern of fibrosis.
Conclusions:
The p.Pro108Alafs*9 mutation is associated with HCM, high penetrance, and disease onset in middle age.
Keywords:
Cardiomyopathy; Hipertrofia; Hypertrophy; MYBPC3 mutation; Miocardiopatía; Muerte súbita; Mutación en MYBPC3; Proteína truncada; Sudden death; Truncated protein.
Copyright © 2016 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Adult
-
Age of Onset
-
Aged
-
Cardiomyopathy, Hypertrophic, Familial / epidemiology
-
Cardiomyopathy, Hypertrophic, Familial / genetics*
-
Cardiomyopathy, Hypertrophic, Familial / metabolism
-
Carrier Proteins / genetics*
-
Carrier Proteins / metabolism
-
DNA / genetics*
-
DNA Mutational Analysis
-
Echocardiography
-
Female
-
Founder Effect
-
Genotype
-
Humans
-
Male
-
Middle Aged
-
Mutation*
-
Myosins
-
Pedigree
-
Spain / epidemiology
-
Survival Rate / trends
Substances
-
Carrier Proteins
-
myosin-binding protein C
-
DNA
-
Myosins